07 TAUTel Aviv University (TAU) is Israel’s largest institution of higher education leading cutting edge science. It is ranked among the world’s top universities, and in Israel ranked first in citations per faculty member. The university’s ground-breaking research and leading researchers have been acknowledged by many prestigious prizes. Justly, The Dan David Foundation is headquartered at TAU and annually awards three prizes of 1 million US$ each for outstanding achievements. TAU’s proficiency in various research fields has led to many fruitful mutual projects under national and international programs including the EC framework programs. Around 30,000 students attend TAU’s 9 faculties, 25 schools with 105 departments, and over a hundred research centres and institutes. VPK acquired her expertise in glycobiology and immunology of humans and mouse models in the laboratory of Prof. Ajit Varki at The University of California San Diego. She recently joined the Faculty of Life Sciences at TAU and has a lab space in the Department of Cell Biology and Immunology. The department comprises 13 groups covering active research in immunology, virology and therapy, human genetic diseases, nanomedicine, and bioinformatics. As a new investigator, VPK received start-up funds to cover essential equipment needed for this project including HPLC, glycan microarray printer and scanner, as well as other common lab equipment (incubators, PCR, centrifuges, refrigerators, freezers etc). Tel-Aviv University greatly invests in high technologies and the equipment accessible for scientists is superb. Such dedicated shared equipment will be available through the ZABAM Instrumentation and Service Centre and The Centre for Nanoscience and Nanotechnology. More importantly, due to the stimulating atmosphere and its central location, TAU consistently engages the highly motivated and the brightest graduate students in Israel every year that directly reflects on the successful implementation of the proposal.

TAU will analyse the immune response of several targets responsible for BHV damage in order to investigate the immune response to BJV and correlate the nature and magnitude of the response to the clinical outcome of a large informative international cohort of BHV recipients.

Contributors to TRANLINK: 

  • Dr. Vered Padler-Karavani, PhD, Assistant Professor at the Department of Cell Research and Immunology, Faculty of Life Sciences,
  • Prof. Dan Peer, PhD, Professor at the Department of Cell Research and Immunology, Faculty of Life Sciences,
  • Prof. Itai Benhar, PhD, Professor at the Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences.